4DMedical (4DX) Q3 2026 TU earnings summary

Executive summary

• Achieved significant commercial momentum for CT:VQ™, with adoption by five leading U.S. Academic Medical Centres and a 90-day evaluation at Mayo Clinic.

• Entered a contract with GlaxoSmithKline to supply quantitative lung imaging analytics for pulmonary drug development.

• Secured CE Mark and UKCA certifications for CT:VQ™, enabling immediate commercial deployment in the EU and UK.

• Completed two institutional placements totaling $233 million to fund expansion and maintain balance sheet strength.

• Included in the S&P/ASX 200 Index, increasing visibility among institutional investors.

Financial highlights

• Pro forma cash balance of $282.7 million as of 31 March 2026.

• Underlying SaaS revenue up 24% year-to-date FY26 vs prior corresponding period (pcp).

• Operating revenue for YTD FY26 was $5.0 million, up 12% vs pcp, with gross margins exceeding 90%.

• Receipts from customers in Q3 FY26 increased 18% vs pcp to $1.4 million.

• Net operating cash outflows for Q3 FY26 were ($10.2 million), down 10.3% vs pcp.

Outlook and guidance

• Regulatory clearances in the U.S., EU, UK, Canada, and New Zealand position CT:VQ™ for global commercial rollout.

• Focus on expanding commercial adoption, customer onboarding, and evidence generation across priority markets.

• Priority for the remainder of 2026 is to establish thought leadership and drive scan volume growth.